Association of Diabetes Care & Education Specialists

Login
Home Page
Your Personalized Guide
to AADE Resources
AADE GPS
My Profile
My Memberships
My Purchases
MY AADE NETWORK
My Open Invoices
Join Online
Online Store
Events
Make a Donation
Access My Learning
Access AADE7 System
Find a Diabetes Educator
Find an Accredited DSME Program
Apply For/Manage My DEAP Application

Event Profile

BAQSIMI® (glucagon) nasal powder 3 mg: The First and Only Glucagon With Nasal Administration

August 5, 2021

Location: Online

Website: https://www.diabeteseducator.org/event/WEBI210727


For more information, please see Full Prescribing Information and Instructions for Use included with the BAQSIMI device.

Event Date: Thursday, August 5, 2021
Event Time: 1:00-2:00 PM ET 

Please Note: All times are Eastern. Our webinars begin at 1:00 PM Eastern / 12:00 PM Central / 11:00 AM Mountain / 10:00 AM Pacific. 


         


Description

A severe hypoglycemia episode can occur unexpectedly. It is important that healthcare providers prepare patients and caregivers to successfully navigate the severe hypoglycemia rescue moment. This presentation will address some common misconceptions that healthcare providers may have about severe hypoglycemia. Additionally, this presentation will provide an overview of BAQSIMI (glucagon) nasal powder 3 mg, which is indicated for severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.

This webinar is sponsored by Lilly USA, LLC.

Objectives

After completing this activity, participants should be able to:
  • Recognize some common myths about severe hypoglycemia and how to address them
  • Understand the efficacy and safety profile of BAQSIMI
  • Understand proper usage and administration of BAQSIMI
  • Discuss how to help patients get off to a good start with BAQSIMI 


Intended Audience

This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, nurse practitioners, clinical nurse specialists, physicians, physician assistants, and other healthcare providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.


INDICATION

BAQSIMI® (glucagon) nasal powder is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure, insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, BAQSIMI administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. BAQSIMI is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. BAQSIMI is contraindicated in patients with a prior hypersensitivity reaction.

BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions
Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, and itchy nose, throat and eyes.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given BAQSIMI. In patients taking indomethacin, BAQSIMI may lose its ability to raise blood glucose or may even produce hypoglycemia. BAQSIMI may increase the anticoagulant effect of warfarin.

GN HCP ISI NOV2020

Please see Full Prescribing Information including Patient Information provided. Please see Instructions for Use included with the device.


BAQSIMI® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.



PP-GN-US-1014 06/2021 © Lilly USA, LLC 2021. All rights reserved.


Debbie Hinnen, APN, CDCES, BC-ADM, FAAN, FADCES
Advanced Practice Nurse and Certified Diabetes Care and Education Specialist
University of Colorado Health
Memorial Hospital Diabetes Center
Colorado Springs, Colorado

Debbie Hinnen, APN, CDCES, BC-ADM, FAAN, FADCES, is an advanced practice nurse and certified diabetes care and education specialist at the University of Colorado Health Memorial Hospital Diabetes Center in Colorado Springs. She is a faculty member in the College of Nursing at the University of Colorado and the graduate nursing program at Wichita State University, in Wichita, Kansas, graduating magna cum laude. Ms. Hinnen is a board-certified advanced diabetes manager.

Ms. Hinnen is a Fellow of the American Academy of Nursing and the Association of Diabetes Care & Education Specialists (ADCES), and a member of the American Diabetes Association (ADA). She is currently serving on the ADA board for Colorado and is a past national president for the ADCES. Ms. Hinnen’s publications focusing on diabetes span over three decades, with her most recent articles published in Journal of the American Association of Nurse Practitioners, Diabetes Spectrum, and Journal of Diabetes Science and Technology. Ms. Hinnen is the recipient of several awards and honors, including Outstanding Diabetes Educator from the ADA and the Distinguished Service Award of the ADCES.

INDICATION

BAQSIMI® (glucagon) nasal powder is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure, insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, BAQSIMI administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. BAQSIMI is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. BAQSIMI is contraindicated in patients with a prior hypersensitivity reaction.

BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions
Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, and itchy nose, throat and eyes.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given BAQSIMI. In patients taking indomethacin, BAQSIMI may lose its ability to raise blood glucose or may even produce hypoglycemia. BAQSIMI may increase the anticoagulant effect of warfarin.

GN HCP ISI NOV2020

Please see Full Prescribing Information including Patient Information provided. Please see Instructions for Use included with the device.


BAQSIMI® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.



PP-GN-US-1014 06/2021 © Lilly USA, LLC 2021. All rights reserved.

Price

This webinar is FREE for ADCES members and non-members.

INDICATION

BAQSIMI® (glucagon) nasal powder is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure, insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, BAQSIMI administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. BAQSIMI is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. BAQSIMI is contraindicated in patients with a prior hypersensitivity reaction.

BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions
Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, and itchy nose, throat and eyes.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given BAQSIMI. In patients taking indomethacin, BAQSIMI may lose its ability to raise blood glucose or may even produce hypoglycemia. BAQSIMI may increase the anticoagulant effect of warfarin.

GN HCP ISI NOV2020

Please see Full Prescribing Information including Patient Information provided. Please see Instructions for Use included with the device.


BAQSIMI® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.



PP-GN-US-1014 06/2021 © Lilly USA, LLC 2021. All rights reserved.

Test Your Computer

To ensure that your participation is successful, please test your system as soon as possible so if you do have technical challenges, you will have time to get them sorted out. Click here to test your computer.

System Requirements

While you can participate with a 56K dial-up internet connection, it is recommended that you have a high-speed broadband (or better) internet connection. Please be sure you close as many open programs on your system as possible. Click here for operating system requirements.

Technical Support

Contact ADCES Member Engagement at 800-338-3633 option 3 or email education@adces.org

INDICATION

BAQSIMI® (glucagon) nasal powder is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 4 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications
BAQSIMI is contraindicated in patients with pheochromocytoma because of risk of substantial increase in blood pressure, insulinoma because of risk of hypoglycemia, and known hypersensitivity to glucagon or to any of the excipients in BAQSIMI. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension.

Warnings and Precautions
BAQSIMI is contraindicated in patients with pheochromocytoma because glucagon may stimulate release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, BAQSIMI administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. BAQSIMI is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of BAQSIMI, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. BAQSIMI is contraindicated in patients with a prior hypersensitivity reaction.

BAQSIMI is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for BAQSIMI administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions
Most common (≥10%) adverse reactions associated with BAQSIMI are nausea, vomiting, headache, upper respiratory tract irritation (i.e., rhinorrhea, nasal discomfort, nasal congestion, cough, and epistaxis), watery eyes, redness of eyes, and itchy nose, throat and eyes.

Drug Interactions
Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given BAQSIMI. In patients taking indomethacin, BAQSIMI may lose its ability to raise blood glucose or may even produce hypoglycemia. BAQSIMI may increase the anticoagulant effect of warfarin.

GN HCP ISI NOV2020

Please see Full Prescribing Information including Patient Information provided. Please see Instructions for Use included with the device.


BAQSIMI® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.



PP-GN-US-1014 06/2021 ©Lilly USA, LLC 2021. All rights reserved.

Share with friends: